

DIN EN ISO 11615:2018-04 (E)

Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of regulated medicinal product information (ISO 11615:2017)

Contents		Page
European foreword		5
Foreword		6
Introduction		7
1	Scope	9
2	Normative references	9
3	Terms, definitions and abbreviated terms	10
4	Message exchange format	21
5	Conformance terminology and context as it relates to the ISO IDMP standards and corresponding IDMP technical specifications	22
6	Concepts required for the unique identification of Medicinal Products	22
6.1	General considerations	22
6.2	Authorised Medicinal Products	22
6.3	Investigational Medicinal Products	23
6.4	Concepts required for the unique identification of a Medicinal Product and the association with PhPID(s)	23
6.5	Concepts required for the unique identification of Medicinal Products and the association with the marketing authorisation number	23
6.6	Concepts required for the unique identification of Medicinal Products and the association with data carrier identifiers	24
7	Description of the information modelling principles and practices	25
7.1	General considerations	25
7.2	Conceptual overview diagrams	25
7.3	High-level diagrams	26
7.4	Detailed description diagrams	26
7.4.1	General	26
7.4.2	Relationships between classes	27
7.4.3	Attributes of classes	28
7.4.4	Generalised classes and patterns	28
7.4.5	Translation and language	28
8	Identifying characteristics for authorised Medicinal Products	28
8.1	Primary identifiers — General considerations	28
8.2	Medicinal Product Identifier (MPID)	29
8.2.1	General considerations	29
8.2.2	MPID code segments	29
8.3	Packaged Medicinal Product Identifier (PCID)	30
8.3.1	General considerations	30
8.3.2	Package description (PCID) code segment	31
8.4	Medicinal Product Batch Identifier (BAID1)	31
8.5	Medicinal Product Batch Identifier (BAID2)	31
9	Information for an authorised Medicinal Product	32
9.1	Authorised Medicinal Product — Information overview	32
9.1.1	General	32
9.1.2	Medicinal Product	32

9.1.3	Medicinal Product name	32
9.1.4	Header	33
9.1.5	Manufacturer/Establishment (organisation)	33
9.1.6	Marketing authorisation	33
9.1.7	Packaged Medicinal Product	33
9.1.8	Pharmaceutical product	33
9.1.9	Ingredient	33
9.1.10	Clinical particulars	33
9.2	Medicinal Product	33
9.2.1	General	33
9.2.2	Detailed description of Medicinal Product information	34
9.3	Marketing authorisation	36
9.3.1	General	36
9.3.2	Detailed description of marketing authorisation information	41
9.4	Organisation	46
9.4.1	General	46
9.4.2	Detailed description of organisation information	46
9.5	Manufacturer/Establishment (organisation)	49
9.5.1	General	49
9.5.2	Detailed description of manufacturer/establishment (organisation) information	49
9.6	Packaged Medicinal Product, including manufactured item and device	50
9.6.1	General	50
9.6.2	Detailed description of Packaged Medicinal Product information	51
9.7	Ingredient, substance and strength	60
9.7.1	General	60
9.7.2	Detailed description of ingredients, substance and strength information	60
9.8	Pharmaceutical product and device	63
9.8.1	General	63
9.8.2	Detailed description of pharmaceutical product and device information	63
9.9	Clinical particulars	65
9.9.1	General	65
9.9.2	Detailed description for clinical particulars information	66
10	Identifying characteristics for Investigational Medicinal Products	70
10.1	General	70
10.2	Primary identifiers	70
10.2.1	General considerations	70
10.3	Investigational Medicinal Product Identifier (IMPID)	71
10.3.1	General considerations	71
10.3.2	IMPID code segments	71
10.4	Investigational Medicinal Product Package Identifier (IPCID)	72
10.4.1	General provisions	72
10.4.2	Package description code segment	72
10.5	Investigational Medicinal Product Batch Identifier (BAID1)	73
10.6	Investigational Medicinal Product Batch Identifier (BAID2)	73
11	Information for an Investigational Medicinal Product	73
11.1	General	73
11.2	Conceptual overview of the information for an Investigational Medicinal Product	73
11.2.1	General	73
11.2.2	Investigational Medicinal Product	74
11.2.3	Investigational Medicinal Product name	74
11.2.4	Header	74
11.2.5	Manufacturer/Establishment (organisation)	74
11.2.6	Clinical trial authorisation	75
11.2.7	Investigational Packaged Medicinal Product	75
11.2.8	Pharmaceutical product	75
11.2.9	Ingredient	75
11.2.10	Clinical particulars	75

11.3	Investigational Medicinal Product	75
11.3.1	General.....	75
11.3.2	Detailed description of Investigational Medicinal Product information.....	75
11.4	Clinical trial authorisation	78
11.4.1	General.....	78
11.4.2	Detailed description of clinical trial authorisation information.....	78
11.5	Manufacturer/Establishment (organisation).....	82
11.6	Investigational Packaged Medicinal Product.....	82
11.7	Pharmaceutical product.....	80
11.7.1	General.....	80
11.7.2	Pharmaceutical product.....	81
11.7.3	Dosing and route of administration	81
11.8	Ingredient.....	81
11.9	Clinical particulars.....	82
11.10	PhPID sets	82
11.11	Device nomenclature.....	82
11.12	Device batch identifier	82
11.13	Physical characteristics	82
11.14	Other characteristics.....	82
	Annex A (normative) Full model — Authorised Medicinal Products detailed diagram.....	83
	Annex B (normative) Full model — Investigational Medicinal Products detailed diagram	84
	Bibliography	85